Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | S100A9 | P06702 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 4/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181852 | 0.78 | TSHR (0.51) | FFAR4ALDH1A1HTT | |
| SCHEMBL2635603 | 0.78 | S100A9 (0.53) | CNR2S100A9TNNI3KRORCSCN3A | |
| SCHEMBL1415662 | 0.76 | EPAS1 (0.47) | S100A9SLC6A4SLC6A3 | |
| SCHEMBL2443453 | 0.76 | S100A9 (0.38) | CNR2S100A9SLC6A4SLC6A3TNNI3K | |
| SCHEMBL20007679 | 0.74 | NOTUM (0.43) | CNR2S100A9FFAR4ALDH1A1RORC | |
| SCHEMBL17860810 | 0.74 | CCR2 (0.40) | CCR2SLC6A4ALDH1A1 | |
| SCHEMBL29553294 | 0.73 | ALDH1A1 (0.41) | CNR2S100A9SLC6A4SLC6A3FFAR4 | |
| SCHEMBL15627060 | 0.73 | ALDH1A1 (0.41) | CNR2S100A9SLC6A4SLC6A3FFAR4 | |
| SCHEMBL3884379 | 0.73 | EPAS1 (0.46) | CNR2S100A9CCR2ALDH1A1RORC | |
| SCHEMBL9978249 | 0.73 | PTPN1 (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2651412-A2 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | Beth Israel Deaconess Medical Center (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012082862-A2 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082862-A2 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, NR5A1, ESRRB | CNR2 251/4885S100A9 4299/4885CCR2 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.